Leerink Partners Maintains Outperform on Guardant Health, Raises Price Target to $155

Benzinga · 1d ago
Leerink Partners analyst Puneet Souda maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $115 to $155.